Product Name :
ARS-1630
Description:
ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1.
CAS:
1698055-86-5
Molecular Weight:
430.84
Formula:
C21H17ClF2N4O2
Chemical Name:
(7R)-1-{4-[6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl}prop-2-en-1-one
Smiles :
C=CC(=O)N1CCN(CC1)C1=NC=NC2=C1C=C(Cl)C(C1=C(O)C=CC=C1F)=C2F
InChiKey:
ZRPZPNYZFSJUPA-UHFFFAOYSA-N
InChi :
InChI=1S/C21H17ClF2N4O2/c1-2-16(30)27-6-8-28(9-7-27)21-12-10-13(22)17(19(24)20(12)25-11-26-21)18-14(23)4-3-5-15(18)29/h2-5,10-11,29H,1,6-9H2
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1.|Product information|CAS Number: 1698055-86-5|Molecular Weight: 430.84|Formula: C21H17ClF2N4O2|Chemical Name: (7R)-1-{4-[6-chloro-8-fluoro-7-(2-fluoro-6-hydroxyphenyl)quinazolin-4-yl]piperazin-1-yl}prop-2-en-1-one|Smiles: C=CC(=O)N1CCN(CC1)C1=NC=NC2=C1C=C(Cl)C(C1=C(O)C=CC=C1F)=C2F|InChiKey: ZRPZPNYZFSJUPA-UHFFFAOYSA-N|InChi: InChI=1S/C21H17ClF2N4O2/c1-2-16(30)27-6-8-28(9-7-27)21-12-10-13(22)17(19(24)20(12)25-11-26-21)18-14(23)4-3-5-15(18)29/h2-5,10-11,29H,1,6-9H2|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 100 mg/mL (232.{{Fremanezumab} MedChemExpress|{Fremanezumab} Neuronal Signaling|{Fremanezumab} Biological Activity|{Fremanezumab} Data Sheet|{Fremanezumab} supplier|{Fremanezumab} Autophagy} 10 mM).{{Deucravacitinib} medchemexpress|{Deucravacitinib} Epigenetics|{Deucravacitinib} Protocol|{Deucravacitinib} Description|{Deucravacitinib} custom synthesis|{Deucravacitinib} Cancer} |Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:23927631 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|KRASG12C is recently identified to be potentially druggable by allele-specific covalent targeting of Cys-12 in vicinity to an inducible allosteric switch II pocket (S-IIP). Success of this approach requires active cycling of KRASG12C between its active-GTP and inactive-GDP conformations as accessibility of the S-IIP is restricted only to the GDP-bound state. This strategy proves feasible for inhibiting mutant KRAS in vitro.|Products are for research use only. Not for human use.|